Position in SVTR
Snapshot 2026-10-23- Startup SignalsRankedof 2,327↓62
- Life SciencesRankedof 243↓4
About
Qilingyun is a Hangzhou-based company founded in 2023 that develops AI-powered physical therapy robots and intelligent massage therapy systems, combining proprietary algorithms with smart production lines for health and rehabilitation scenarios.
Capital graph
Funding history
- 2026-06Series A
Investors · 中嘉健康产业集团, CICC CapitalSource · SVTR Weekly #161 ↗
Comparable companies· by market
This company
BusinessLatest roundTotal raisedDate- 启灵云
AI physiotherapy robots and smart massage therapy systems for wellness and rehabilitation settings
Series A · 2026-06
—
United States
BusinessLatest roundTotal raisedDate- Vivodyne
Robotic automation to produce human tissue for faster drug testing
Series A · $40M · 2025-05
$40M - Optain Health
Early screening through AI and robotic retinal imaging and remote ophthalmology
Series A · $26M · 2025-09
$26M - Lila Sciences
Uses AI to analyze data, design experiments and direct robotic systems to carry out experiments in the life sciences, chemistry and materials science
Series A · $550M · 2025-10
$550M
China
BusinessLatest roundTotal raisedDateEurope
BusinessLatest roundTotal raisedDate- Vitestro
Developed a device that integrates AI with ultrasound imaging and robotics to automate blood collection
Series B · $120M · 2026-03
$120M - LabGenius
Machine learning and robotic automation to discover and optimize therapeutic antibodies
Series B · $45M · 2024-05
$45M - Nami Surgical
Miniature ultrasonic medical devices for surgery; high-performance small ultrasonic scalpels designed to overcome obstacles in robot-assisted surgery
Undisclosed · $4M · 2024-05
$4M
Other / unspecified
BusinessLatest roundTotal raisedDate- Intrepid Labs
Autonomous labs combining AI, robotics and chemistry to accelerate drug compound formulation
Seed · $11M · 2025-05
$11M - HD
Chatbots for healthcare
Undisclosed · $6M · 2024-04
$6M - Scopia Surgical
AI surgical navigation software combining real-time spatial intelligence and patient-specific digital twins for robot-assisted and minimally invasive soft-tissue surgery
Pre-Seed · $3M · 2026-09
$3M
Confirmed rounds only. Matched on subsector, sector, stage and funding scale — each verifiable on the company profiles.
Investors that may fit
Dimension Capital
10 Life Sciences deals in the last 24 months · 5 at a nearby stage · 1 in East China
Request intro →OrbiMed Advisors
9 Life Sciences deals in the last 24 months · 5 at a nearby stage · 4 in East China
Request intro →Qiming Venture Partners
9 Life Sciences deals in the last 24 months · 6 at a nearby stage · 7 in East China
Request intro →Lilly Asia Ventures
8 Life Sciences deals in the last 24 months · 6 at a nearby stage · 7 in East China
Request intro →HongShan
7 Life Sciences deals in the last 24 months · 3 at a nearby stage · 6 in East China
Request intro →Matrix Partners China
6 Life Sciences deals in the last 24 months · 6 at a nearby stage · 4 in East China
Request intro →Ranked by each firm’s deals in this sector over the last 24 months, weighted by nearby stage and shared geography. Indicative only — no rating judgment.